Imidazoquinoline TLR7 Modulators for Selective Viral Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases characterized by Toll-like receptor 7 (TLR7) activation lack effective compounds that can selectively activate TLR7 for immunostimulatory signaling, which is crucial for preventing or treating viral infections.
Innovation Solution
Development of specific compounds, such as those represented by Formula Ia, which are designed to selectively activate TLR7, potentially used in pharmaceutical compositions to treat or prevent viral infections, either alone or in combination with other active agents like interferons and HCV NS3 protease inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecules are designed to activate TLR7, then immunostimulatory signaling is enhanced, but selectivity for TLR7 over other TLRs must be maintained
Solution Approach 1:
The patent applies local quality by designing specific functional groups at particular positions on the purine core structure. The imidazoquinoline moiety at position 2 and the amino group at position 6 are strategically placed to interact with specific residues in the TLR7 binding pocket, providing selective activation while maintaining overall structural simplicity
Solution Approach 2:
The patent employs parameter changes by systematically varying substituents at positions 2, 6, and other positions on the purine core. By changing the size, polarity, and steric properties of these substituents, the compounds achieve optimal binding affinity and selectivity for TLR7 while maintaining drug-like molecular weights and physicochemical properties
2Reliability
If compounds are developed for TLR7 activation, then therapeutic efficacy against viral infections is improved, but pharmacological selectivity must be maintained to avoid off-target effects
Solution Approach 1:
The patent uses the imidazoquinoline intermediate structure as a mediator that specifically bridges the compound and TLR7. This intermediate moiety acts as a recognition element that is selectively bound by TLR7 but not by other TLRs, thereby mediating selective immunostimulatory signaling while avoiding off-target effects on other immune receptors
Solution Approach 2:
The patent converts the potential harm of broad immune activation into benefit by designing compounds that exploit the specific structural features of TLR7. The compounds are designed to be recognized specifically by TLR7's unique binding pocket, thereby converting what could be non-specific immune activation into targeted, beneficial immunostimulatory signaling
Data Source
AI summary
The present application provides for a compound of Formula (I) or (II): or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional active agent.